TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6679507
Drug: Diazoxide (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (3-5 mg/kg; mean dose 253.8 mg)
Study: 21288209
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg)
Study: 15492491
Drug: Higher adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher adherence to early treatment for JCP
Study: 15492491
Drug: Low adherence
Normalized name: dressing,low adherence and wound contact materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low adherence to early treatment for JCP
Study: 9001779
Drug: Gestrinone (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone (Group G)
Study: 7029276
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (doses that reduced heart rate by 25%)
Study: 26886327
Drug: Cefaclor standard
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor standard release (SF) 750 mg
Study: 26886327
Drug: Cefaclor modified
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor modified release form (MRF) 750 mg
Study: 23074432
Drug: Intensive counselling
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive counselling or a combination of intensive counselling and nicotine replacement therapy (NRT)
Study: 9863502
Drug: Fansidar one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fansidar one tablet weekly
Study: 24417563
Drug: Peri-implant defect
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant defect reconstruction with porous titanium granules
Study: 22288883
Drug: Saline irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline irrigation (30 mL/kg) under the diaphragm
Study: 18777489
Drug: Muraglitazar 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muraglitazar 2.5 mg plus metformin
Study: 23086138
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg
Study: 1998019
Drug: Methyl prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl prednisolone (16 mg in 40 cc saline, concentration 40 mg%)
Study: 1998019
Drug: Gel-saline double-lumen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-saline double-lumen implant with 40 cc saline
Study: 6359384
Drug: Amoxycillin (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (375 mg, three times daily for 7 days)
Study: 6359384
Drug: Cefaclor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (250 mg, three times daily for 7 days)
Study: 31448789
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day after an initial loading dose of 75 mg/kg over 30 min.
Study: 31448789
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin/tazobactam (TZP) 300 mg/kg/day divided into four doses, not exceeding 16 g/day.
Study: 30297911
Drug: Neoadjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Study: 30297911
Drug: Adjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant ipilimumab 3 mg kg−1 and nivolumab 1 mg kg−1
Study: 20680859
Drug: Medicine companions
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine companions (MCs) chosen by participants for ART adherence support
Study: 18203070
Drug: Extended Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Daily Dialysis with filtration (EDDf)
Study: 12468775
Drug: ZK200775 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK200775 (dose group 2: 525 mg in 48 hours)
Study: 12468775
Drug: ZK200775 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK200775 (dose group 1: 262.5 mg in 48 hours)
Study: 12468775
Drug: ZK200775 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK200775 (dose group 3: 105 mg over 6 hours)
Study: 7609861
Drug: Amitriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (up to 100 mg/day)
Study: 2559129
Drug: Cepharanthin (Ceph.)
Normalized name: Cephalanthus occidentalis bark extract
DrugBank: Cepharanthine (DB16824)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cepharanthin (Ceph.) at a dose of 1 mg/kg
Study: 619829
Drug: Nurse intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse intervention to improve medication compliance
Study: 19502023
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TDS) patch
Study: 16838228
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of tolevamer per day
Study: 16838228
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of tolevamer per day
Study: 16838228
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of vancomycin per day
Study: 9205815
Drug: Labetalol (0.99
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.99 mg per kg of IBW)
Study: 9205815
Drug: Nebivolol (0.073
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (0.073 mg per kg of IBW)
Study: 3763079
Drug: 2000 mL
Normalized name: TPN Bag 2000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mL Plasma‐Lyte A
Study: 3763079
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL 5% albumin (colloid infusion)
Study: 3763079
Drug: 1000 mL
Normalized name: TPN Bag 1000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL Plasma‐Lyte A
Study: 30179153
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (combined aspirin, clopidogrel and dipyridamole)
Study: 30179153
Drug: Guideline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline therapy (combined aspirin and dipyridamole, or clopidogrel alone)
Study: 12860493
Drug: Adalimumab 0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.25, 0.5, 1, 3, or 5 mg/kg i.v.
Study: 6839972
Drug: Atrioventricular sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrioventricular sequential pacemaker (group B)
Study: 24960402
Drug: Pertuzumab 840
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2‐6 (Arm A)
Study: 9475319
Drug: Cord insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord insulin-like growth factor-I or glucagon concentrations
Study: 2963522
Drug: Celiprolol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200, 400 or 600 mg once daily)
Study: 2963522
Drug: Chlorthalidone (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5, 25 or 37.5 mg once daily)
Study: 15196519
Drug: Light touch
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light touch (L)
Study: 11743267
Drug: Dopamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (3 microg./kg. per minute infusion)
Study: 9718103
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment and 12-step groups
Study: 9718103
Drug: Outpatient mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient mental health treatment and 12-step group attendance
Study: 7655203
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with prednisolone 1% eye drops (Inflanefran forte) 5 times per day
Study: 7655203
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 4 mg dexamethasone (Fortecortin) immediately at the end of surgery; topical therapy as in group A
Study: 5801346
Drug: Intraperitoneal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal fluid infusion with normal saline and 28 mEq of potassium chloride per litre
Study: 5801346
Drug: Intraperitoneal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal fluid infusion with half-strength Darrow's solution
Study: 16453248
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Jarsin (extract of St John's wort)
Study: 16453248
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Jarsin (extract of St John's wort)
Study: 15278047
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg per day for 7 days
Study: 15278047
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg per day for 28 days
Study: 8449588
Drug: Teicoplanin therapy
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin therapy (800 mg initially, then 400 mg at weekly intervals)
Study: 3300316
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg three times a day
Study: 3300316
Drug: Trimethoprim/sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg) twice daily
Study: 3300316
Drug: Norfloxacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (both doses)
Study: 28601972
Drug: TAK-228 8-mg
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 8-mg QDx3d QW plus paclitaxel 80 mg/m2
Study: 28601972
Drug: TAK-228 10-mg
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 10-mg QDx3d QW plus paclitaxel 80 mg/m2
Study: 24192332
Drug: Zidovudine during
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour
Study: 18176972
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/d plus 5-ASA 2 g/d daily for 4 weeks
Study: 18176972
Drug: 5-ASA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA 2 g/d alone for 4 weeks
Study: 12683261
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with a combination of AA (Arachidonic Acid) and DHA (Docosahexaenoic Acid) and antioxidants (vitamins E and C)
Study: 12683261
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic treatment
Study: 6202571
Drug: Mexiletine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (600 mg daily, 200 mg every 8 hours)
Study: 6180562
Drug: Mexiletine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (600 mg daily)
Study: 22999066
Drug: Gin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin (30 g alcohol/d)
Study: 22550117
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-7 (rhIL-7) at a dose of 20 µg/kg
Study: 17852016
Drug: Sequential trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential trial design
Study: 9260077
Drug: Caffeinated cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated cola (33 mg/8 oz)
Study: 3812057
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment plus significant other support condition
Study: 17012443
Drug: Both 12-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 12-hour and 24-hour magnesium sulfate (MgSO4) therapy
Study: 11078488
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg once daily
Study: 11078488
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg once daily
Study: 24841020
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 1 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Study: 24841020
Drug: Ilioinguinal-iliohypogastric nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal-iliohypogastric nerve block with 0.3 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Study: 23545284
Drug: CVI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVI of 5‐Fluorouracil (5‐FU), 225 mg/m(2) per day, 7 days per week plus pelvic hyperfractionated radiation (HRT), 45.6 Gy at 1.2 Gy twice daily plus a boost of 9.6 to 14.4 Gy for T3 or T4 cancers (Arm 1)
Study: 20004739
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition designed to provide 100% of measured resting energy expenditure (REE)
Study: 20004739
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition designed to provide 100% of measured REE
Study: 20004739
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (140% of estimated energy expenditure)
Study: 18262380
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment using sulfadoxine‐pyrimethamine
Study: 18262380
Drug: Weekly chemoprophylaxis
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemoprophylaxis with chloroquine
Study: 18262380
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment using three doses of chloroquine
Study: 16841626
Drug: Duloxetine (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40-120 mg/day)
Study: 12798153
Drug: EC40 (40%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC40 (40% chlorhexidine) applied once or twice over 2 weeks
Study: 10900675
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens and combined progestin treatment
Study: 1503446
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (4 x 850 mg tablets taken 5 min before Cipro)
Study: 6147695
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining followed by 7 weekly sessions of real-life exposure
Study: 24613367
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron administration (510 mg elemental iron as ferumoxytol)
Study: 7693422
Drug: Cyclophosphamide 100
Normalized name: cyclophosphamide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/m2 orally on days 1 to 14, Methotrexate 40 mg/m2 intravenously on days 1 and 8, Fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF)
Study: 7693422
Drug: Fluorouracil 600
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 600 mg/m2, Epirubicin 50 mg/m2, Cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals
Study: 23566267
Drug: Subcutaneous 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 1.0% lidocaine injection
Study: 19098852
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with peginterferon plus ribavirin for 48-68 weeks (44 weeks after HCV RNA negative)
Study: 15915396
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) epinephrine
Study: 7899535
Drug: L-5-hydroxytryptophan (L-5-HTP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L-5-HTP, 200 mg PO)
Study: 7899535
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg PO)
Study: 857761
Drug: High epidural
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High epidural analgesia (bupivacaine injections into the epidural space)
Study: 28551167
Drug: Brolucizumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab (6 mg/50 μl)
Study: 11591407
Drug: 1.125 g
Normalized name: progesterone 45 mg in 1.125 g VAGINAL GEL [Crinone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.125 g of Crinone 4% and 8% or 2.25 g of Crinone 8% (containing 45, 90, and 180 mg of P per application)
Study: 11591407
Drug: Vaginal P
Normalized name: Vaginal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal P gel Crinone administered to estrogenized women
Study: 7524044
Drug: Entex LA
Normalized name: Entex LA
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entex LA tablets (sustained-release, carbomer-based)
Study: 7524044
Drug: Entex PSE
Normalized name: Entex PSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entex PSE tablets (sustained-release, hydroxypropylcellulose-based)
Study: 7524044
Drug: Branded competitor
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded competitor products (sustained-release)
Study: 2082492
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole
Study: 7593525
Drug: Gonadotrophin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin‐releasing hormone analogues (GnRHa)
Study: 28706429
Drug: Reduced-dose sodium
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose sodium phosphate (NaP) tablets with 2 L of clear liquid (30 tablets)
Study: 17047260
Drug: No model-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: No model-based calculation algorithm or model-based calculation algorithm with a dose kernel unscaled for heterogeneities
Study: 12660409
Drug: Cr (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr (4 x 5 g x day(‐1) x 5 days)
Study: 12660409
Drug: Glucose+Cr (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose+Cr (1 g x (‐1) of body mass twice per day)
Study: 12660409
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g x day(‐1) maintenance
Study: 12660409
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g x day(‐1) maintenance
Study: 6619453
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion at midnight
Study: 31091374
Drug: Alpelisib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (300 mg per day) plus Fulvestrant (500 mg every 28 days and once on day 15)
Study: 21784413
Drug: COMET +
Normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: COMET + treatment-as-usual (TAU)
Study: 15313689
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition group (TPN group), 50 patients
Study: 11273211
Drug: Prednisone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.5 mg/kg daily for 8 weeks
Study: 9294477
Drug: TAM +
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAM + MPA (medroxyprogesterone acetate 500 mg/day orally)
Study: 3779498
Drug: Rapid-sequence induction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-sequence induction with thiopentone (5 mg X kg‐1) and succinylcholine
Study: 3779498
Drug: Elective induction
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective induction with thiopentone (5 mg X kg‐1) and succinylcholine
Study: 22460142
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg
Study: 31713350
Drug: Tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 15 mg (single dose) followed by 15 mg twice daily for 5 days
Study: 25396067
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment
Study: 26276658
Drug: No-statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-statin treatment (Control)
Study: 21348544
Drug: Resveratrol-containing gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol-containing gel applied daily for 60 days on the right side of the face
Study: 18301313
Drug: iomeprol-400 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol-400 (400 mgI/mL, 726 mOsm/kg, N = 76)
Study: 17159170
Drug: All-polyethylene tibial
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-polyethylene tibial implants
Study: 17159170
Drug: Metal-backed tibial
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-backed tibial implants
Study: 6404880
Drug: Ornidazole 500
Normalized name: ornidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 500 mg orally every 12 h for seven days
Study: 6404880
Drug: Phenoxymethylpenicillin 800
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 800 mg orally every 12 h for seven days
Study: 27742968
Drug: Ultrasound-guided intermediate
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intermediate cervical plexus block with 5 ml of 0.75% ropivacaine
Study: 19855076
Drug: Segmental muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental muscle vibration (SMV) at 120 Hz for 30 minutes after each physical therapy session
Study: 25591053
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical therapy